<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM21944-41X-0D-CN6"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 S1462 IS: Simplifying the Generic Drug Application Process Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2021-04-29</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>117th CONGRESS</congress><session>1st Session</session><legis-num>S. 1462</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20210429">April 29, 2021</action-date><action-desc><sponsor name-id="S373">Mr. Cassidy</sponsor> (for himself and <cosponsor name-id="S394">Ms. Smith</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act to simplify the generic drug application process.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Simplifying the Generic Drug Application Process Act</short-title></quote>.</text></section><section id="idEB7258214EB646FC97AADDC23F4E701B"><enum>2.</enum><header>Submission for suitability</header><text display-inline="no-display-inline">Subparagraph (C) of section 505(j)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(2)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="iddd6ac72c77c440d9b9823665914ba32c"><subparagraph id="idB85227106AF64EBBA735FD5EACCE8E2D" indent="up2"><enum>(C)</enum><header>Submission for suitability determinations</header><clause id="id6060B2B2A92841F1A38F8494D3452C6C"><enum>(i)</enum><header>In general</header><text>A person may submit an abbreviated application for a new drug that has a different dosage form or strength from that of a listed drug.</text></clause><clause id="idD894A0B9F3ED4EA3B01452799FF7DAEC"><enum>(ii)</enum><header>Secretary's determination on submission</header><text>The Secretary shall approve or disapprove the submission of such an abbreviated application during the course of its determination whether to receive the application pursuant to section 314.101 of title 21, Code of Federal Regulations (or any successor regulations).</text></clause><clause id="idC471A74519A2483C975E005CC9273DED"><enum>(iii)</enum><header>Approval of submission</header><text>The Secretary shall approve the submission of such an abbreviated application, provided the application is otherwise determined to be eligible to be received, unless the Secretary finds that—</text><subclause id="id5914EF5273314330B15B0BCEF7C43C1E"><enum>(I)</enum><text>clinical investigations are required to be conducted to show the safety and effectiveness of the drug or of any of its dosage forms or strengths which differ from the listed drug; or</text></subclause><subclause id="idD3EE0517E3A342EDAFCB698B14C57661"><enum>(II)</enum><text>any of the proposed changes from the listed drug would jeopardize the safe or effective use of the product so as to necessitate significant labeling changes to address the newly introduced safety or effectiveness problem.</text></subclause></clause><clause id="idA8DD3635FE10433599B2B881BB8BDEC8"><enum>(iv)</enum><header>Disapproval of submission</header><text>If the Secretary disapproves the submission of an abbreviated application under this subparagraph, the application shall be considered not to have been received within the meaning of paragraph (5)(A).</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

